The DOI matches its Crossref record; 76 of the 76 references it cites were found in a registry or an index.
Biochemical and Clinical Aspects of Methotrexate Neurotoxicity
Abstract
Acute, subacute and chronic neurotoxicity have been observed after the administration of high-dose and/or intrathecal methotrexate (MTX). Acute toxicity is usually transient without permanent damage. Subacute and chronic toxicity are associated with changes in the brain and/or the spinal cord which may be progressive and even lead to coma and death in severe cases. It is believed that MTX can induce direct toxic effects to the CNS by damaging the neuronal tissue. Moreover, MTX interferes with the metabolic pathways of folates, excitatory amino acids, homocysteine, S-adenosylmethionine/S-adenosylhomocysteine, adenosine and biopterins, inducing biochemical alterations which have been associated with neurotoxic symptoms. It has been suggested that acute toxicity is partly mediated by adenosine, whereas homocysteine, S-adenosylmethionine/S-adenosylhomocysteine, excitatory amino acids and biopterins may play an important role in the development of subacute and chronic toxicity. A better understanding of the pathogenesis of MTX neurotoxicity would offer the possibility of developing new therapeutic strategies for its treatment or prevention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Glutamate neurotoxicity and diseases of the nervous system
CHOI, D. (1988) · Neuron · doi:10.1016/0896-6273(88)90162-6 · Cited by 7,972
Excitatory Amino Acids as a Final Common Pathway for Neurologic Disorders
Epstein, F. H., Lipton, S. A., & Rosenberg, P. A. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403033300907 · Cited by 2,658
Hyperhomocysteinemia: An Independent Risk Factor for Vascular Disease
Clarke, R., Daly, L., Robinson, K., Naughten, E., Cahalane, S., Fowler, B., & Graham, I. (1991) · New England Journal of Medicine · doi:10.1056/nejm199104253241701 · Cited by 2,161
Excitatory amino acid neurotoxicity and neurodegenerative disease
Meldrum, B., & Garthwaite, J. (1990) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(90)90184-a · Cited by 1,771
Perry, I. J., Morris, R. W., Ebrahim, S. B., Shaper, A. G., Refsum, H., & Ueland, P. M. (1995) · The Lancet · doi:10.1016/s0140-6736(95)92407-8 · Cited by 883
Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis.
Tsai, J. C., Perrella, M. A., Yoshizumi, M., Hsieh, C. M., Haber, E., Schlegel, R., & Lee, M. E. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.14.6369 · Cited by 798
Cronstein, B. N., Naime, D., & Ostad, E. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116884 · Cited by 679
Homocysteine-induced endothelial cell injury in vitro: A model for the study of vascular injury
Wall, R. T., Harlan, J. M., Harker, L. A., & Striker, G. E. (1980) · Thrombosis Research · doi:10.1016/0049-3848(80)90175-9 · Cited by 483
The central nervous system in childhood leukemia.II. Subacute leukoencephalopathy
Price, R. A., & Jamieson, P. A. (1975) · Cancer · doi:10.1002/1097-0142(197502)35:2<306::aid-cncr2820350203>3.0.co;2-j · Cited by 479
Vitamin B-12, vitamin B-6, and folate nutritional status in men with hyperhomocysteinemia
Ubbink, J., Vermaak, W., van der Merwe, A., & Becker, P. (1993) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/57.1.47 · Cited by 461
Acidic amino acids with strong excitatory actions on mammalian neurones
Curtis, D. R., & Watkins, J. C. (1963) · The Journal of Physiology · doi:10.1113/jphysiol.1963.sp007087 · Cited by 417
Neurotoxicity of Commonly Used Antineoplastic Agents
Weiss, H. D., Walker, M. D., & Wiernik, P. H. (1974) · New England Journal of Medicine · doi:10.1056/nejm197407112910205 · Cited by 411
Activation of endogenous factor V by a homocysteine-induced vascular endothelial cell activator.
Rodgers, G. M., & Kane, W. H. (1986) · Journal of Clinical Investigation · doi:10.1172/jci112519 · Cited by 384
Neurotoxicity and Elevated Cerebrospinal-Fluid Methotrexate Concentration in Meningeal Leukemia
Bleyer, W. A., Drake, J. C., & Chabner, B. A. (1973) · New England Journal of Medicine · doi:10.1056/nejm197310112891503 · Cited by 337
Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates.
Allegra, C. J., Chabner, B. A., Drake, J. C., Lutz, R., Rodbard, D., & Jolivet, J. (1985) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)39298-0 · Cited by 335
Allegra, C. J., Drake, J. C., Jolivet, J., & Chabner, B. A. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.15.4881 · Cited by 310
Elevated plasma homocyst(e)ine concentration as a possible independent risk factor for stroke.
Coull, B. M., Malinow, M. R., Beamer, N., Sexton, G., Nordt, F., & de Garmo, P. (1990) · Stroke · doi:10.1161/01.str.21.4.572 · Cited by 308
Plasma homocyst(e)ine levels in men with premature coronary artery disease
Genest, J. J., McNamara, J. R., Salem, D. N., Wilson, P. W. F., Schaefer, E. J., & Malinow, M. R. (1990) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(90)90542-w · Cited by 296
Peylan-Ramu, N., Poplack, D. G., Pizzo, P. A., Adornato, B. T., & Di Chiro, G. (1978) · New England Journal of Medicine · doi:10.1056/nejm197804132981504 · Cited by 294
Mahoney, D. H., Shuster, J. J., Nitschke, R., Lauer, S. J., Steuber, C. P., Winick, N., & Camitta, B. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.5.1712 · Cited by 290
Ochs, J., Mulhern, R., Fairclough, D., Parvey, L., Whitaker, J., Ch'ien, L., Mauer, A., & Simone, J. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.1.145 · Cited by 283
Moderate homocysteinemia--a possible risk factor for arteriosclerotic cerebrovascular disease.
Brattstrom, L. E., Hardebo, J. E., & Hultberg, B. L. (1984) · Stroke · doi:10.1161/01.str.15.6.1012 · Cited by 282
Neurologic sequelae of methotrexate and ionizing radiation: a new classification.
Bleyer, W. A. (1981) · PubMed · Cited by 265
Bottiglieri, T., Godfrey, P., Flynn, T., Carney, M. W., Toone, B. K., & Reynolds, E. H. (1990) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.53.12.1096 · Cited by 258
The Isolation and Characterization of Dihydropteridine Reductase from Sheep Liver
Craine, J. E., Hall, E. S., & Kaufman, S. (1972) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)44767-4 · Cited by 250
Neurological complications of radiotherapy and chemotherapy
Keime-Guibert, F., Napolitano, M., & Delattre, J.-Y. (1998) · Journal of Neurology · doi:10.1007/s004150050271 · Cited by 246
Taurine and neural cell damage
Saransaari, P., & Oja, S. S. (2000) · Amino Acids · doi:10.1007/s007260070003 · Cited by 243
Surtees, R., Leonard, J., & Austin, S. (1991) · The Lancet · doi:10.1016/0140-6736(91)92373-a · Cited by 234
Neurotoxicity of antineoplastic drugs.
Kaplan, R. S., & Wiernik, P. H. (1982) · PubMed · Cited by 233
Enzymatic synthesis of folylpolyglutamates. Characterization of the reaction and its products.
McGuire, J. J., Hsieh, P., Coward, J. K., & Bertino, J. R. (1980) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)70697-8 · Cited by 213
Acute hyperhomocysteinaemia and endothelial dysfunction
Chambers, J. C., McGregor, A., Jean-Marie, J., & Kooner, J. S. (1998) · The Lancet · doi:10.1016/s0140-6736(05)78090-9 · Cited by 208
Baggott, J. E., Vaughn, W. H., & Hudson, B. B. (1986) · Biochemical Journal · doi:10.1042/bj2360193 · Cited by 205
McKeever, M. P., Weir, D. G., Molloy, A., & Scott, J. M. (1991) · Clinical Science · doi:10.1042/cs0810551 · Cited by 202
Quinn, C. T., Griener, J. C., Bottiglieri, T., Hyland, K., Farrow, A., & Kamen, B. A. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.8.2800 · Cited by 189
Neurotoxicity secondary to antineoplastic drugs
Tuxen, M. K., & Hansen, S. W. (1994) · Cancer Treatment Reviews · doi:10.1016/0305-7372(94)90027-2 · Cited by 167
Hayashi, T., Honda, G., & Suzuki, K. (1992) · Blood · doi:10.1182/blood.v79.11.2930.2930 · Cited by 164
Functional methionine synthase deficiency (cblE and cblG): Clinical and biochemical heterogeneity
Watkin, D., & Rosenblatt, D. S. (1989) · American Journal of Medical Genetics · doi:10.1002/ajmg.1320340320 · Cited by 164
Aminophylline for methotrexate-induced neurotoxicity
Bernini, J. C., Fort, D. W., Griener, J. C., Kane, B. J., Chappell, W. B., Kamen, B. A., & Kamen, B. A. (1995) · The Lancet · doi:10.1016/s0140-6736(95)90464-6 · Cited by 163
Transient cerebral dysfunction secondary to high-dose methotrexate.
Walker, R. W., Allen, J. C., Rosen, G., & Caparros, B. (1986) · Journal of Clinical Oncology · doi:10.1200/jco.1986.4.12.1845 · Cited by 159
Lambie, D. G., & Johnson, R. H. (1985) · Drugs · doi:10.2165/00003495-198530020-00003 · Cited by 138
Hyland, Κ., Smith, I., Bottiglieri, T., Perry, J. R., Wendel, U., Clayton, P. T., & Leonard, J. V. (1988) · Neurology · doi:10.1212/wnl.38.3.459 · Cited by 136
DEXTROMETHORPHAN IS EFFECTIVE IN THE TREATMENT OF SUBACUTE METHOTREXATE NEUROTOXICITY
Drachtman, R. A., Cole, P. D., Golden, C. B., James, S. J., Melnyk, S., Aisner, J., & Kamen, B. A. (2002) · Pediatric Hematology and Oncology · doi:10.1080/08880010290057336 · Cited by 134
Refsum, H., Wesenberg, F., & Ueland, P. M. (1991) · PubMed · Cited by 133
Adverse effects of intrathecal methotrexate in children with acute leukemia in remission.
Geiser, C. F., Bishop, Y. M. M., Jaffe, N., et al. (1975) · PubMed · Cited by 128
Mulhern, R. K., Wasserman, A. L., Fairclough, D. C., & Ochs, J. (1988) · Journal of Clinical Oncology · doi:10.1200/jco.1988.6.2.315 · Cited by 124
Refsum, H., Helland, S., & Ueland, P. M. (1989) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1989.179 · Cited by 124
The use of betaine for the treatment of homocystinuria
Smolin, L. A., Benevenga, N. J., & Berlow, S. (1981) · The Journal of Pediatrics · doi:10.1016/s0022-3476(81)80352-6 · Cited by 124
COX, D. W. G., Headley, M. H., & Watkins, J. C. (1977) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1977.tb10707.x · Cited by 117
S-adenosylmethionine levels in psychiatric and neurological disorders: a review
Bottiglieri, T., Hyland, Κ., & Bottiglieri, T. (1994) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1994.tb05405.x · Cited by 116
Excitatory Amino Acid Receptor Potency and Subclass Specificity of Sulfur‐Containing Amino Acids
Pullan, L. M., Olney, J. W., Price, M. T., Compton, R. P., Hood, W. F., Michel, J., & Monahan, J. B. (1987) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1987.tb10024.x · Cited by 105
Neuropsychological Effects of Childhood Cancer Treatment
Copeland, D. R., Dowell, R. E., Fletcher, J. M., Bordeaux, J., Sullivan, M. P., Jaffe, N., Frankel, L. S., Ried, H. L., & Cangır, A. (1988) · Journal of Child Neurology · doi:10.1177/088307388800300113 · Cited by 98
Impact of childhood cancer on the mental health of parents
Dockerty, J. D., Williams, S., McGee, R. O., & Skegg, D. C. G. (2000) · Medical and Pediatric Oncology · doi:10.1002/1096-911x(20001101)35:5<456::aid-mpo3>3.0.co;2-1 · Cited by 88
Grieco, A. J. (1977) · The American Journal of the Medical Sciences · doi:10.1097/00000441-197703000-00001 · Cited by 87
Intracranial calcifications in childhood leukemia
McIntosh, S., FISCHER, D. B., Rothman, S. G., Rosenfield, N. S., Lobel, J. S., & O’Brien, R. T. (1977) · The Journal of Pediatrics · doi:10.1016/s0022-3476(77)80888-3 · Cited by 86
Acute and long-term effects of high-dose methotrexate treatment on homocysteine in plasma and urine.
Refsum, H., Ueland, P. M., & Kvinnsland, S. (1986) · PubMed · Cited by 81
Surtees, R. A. H., Clelland, J. D., & Hann, I. M. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.4.1505 · Cited by 73
Currás‐Collazo, M., & Dingledine, R. J. (1992) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)08949-7 · Cited by 71
Grieve, A., Butcher, S. P., & Griffiths, R. (1992) · Journal of Neuroscience Research · doi:10.1002/jnr.490320108 · Cited by 69
Evidence for cysteine sulfinate as a neurotransmitter
Récasens, M., Varga, V., Nanopoulos, D., Saadoun, F., Vincendon, G., & Bénavidès, J. (1982) · Brain Research · doi:10.1016/0006-8993(82)90839-3 · Cited by 67
Broxson, E. H., Stork, L. C., Allen, R. H., Stabler, S. P., & Kolhouse, J. F. (1989) · PubMed · Cited by 67
Folates and Psychiatric Disorders
Crellin, R. F., Bottiglieri, T., & Reynolds, E. H. (1993) · Drugs · doi:10.2165/00003495-199345050-00001 · Cited by 65
Evidence of brain methyltransferase inhibition and early brain involvement in HIV-positive patients
Keating, J. N., Trimble, K. C., Mulcahy, F., et al. (1991) · The Lancet · doi:10.1016/0140-6736(91)91570-k · Cited by 60
Mulhern, R. K., Ochs, J., Fairclough, D. C., Wasserman, A. L., Davis, K. S., & Williams, J. M. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.6.933 · Cited by 53
Griffiths, R. (1990) · Progress in Neurobiology · doi:10.1016/0301-0082(90)90015-9 · Cited by 52
Calcium Channel Antagonists in the Prevention of Neurotoxicity
Lipton, S. A. (1991) · Advances in pharmacology · doi:10.1016/s1054-3589(08)60038-1 · Cited by 51
Gliotoxic actions of excitatory amino acids
Bridges, R. J., Hatalski, C. G., Shim, S. N., Cummings, B. J., Vijayan, V., Kundi, A., & Cotman, C. W. (1992) · Neuropharmacology · doi:10.1016/0028-3908(92)90128-c · Cited by 48
Thompson, G. A., & Kilpatrick, I. C. (1996) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(96)00097-6 · Cited by 45
Kishi, T., Kawamura, I., Harada, Y., Eguchi, T., Sakura, N., Ueda, K., Narisawa, K., & Rosenblatt, D. S. (1994) · Journal of Inherited Metabolic Disease · doi:10.1007/bf00711591 · Cited by 34
Gool, S. V., Kerschaver, E. V., Brock, P. R., Pottel, H., Hulstaert, F., Vanmechelen, E., Uyttebroeck, A., VOORDE, A. V. D., & Vanderstichele, H. (2000) · Leukemia · doi:10.1038/sj.leu.2401934 · Cited by 28
Croucher, M. J., Thomas, L. S., Ahmadi, H., Lawrence, V., & Harris, J. R. (2001) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0704138 · Cited by 24
Dunlop, J., Grieve, A., Damgaard, I., Schousboe, A., & Griffiths, R. (1992) · Neuroscience · doi:10.1016/0306-4522(92)90385-f · Cited by 21
Weller, M., Marini, A. M., Finiels, F., Martin, B. M., & Paul, S. M. (1993) · European Journal of Pharmacology Environmental Toxicology and Pharmacology · doi:10.1016/0926-6917(93)90004-a · Cited by 20
Effects of methotrexate on astrocytes in primary culture: light and electron microscopic studies
Gregorios, J. B., & Soucy, D. M. (1990) · Brain Research · doi:10.1016/0006-8993(90)90892-f · Cited by 19
Biochemical Model Reactions on the Prooxidative Activity of Homocysteine
Preibisch, G., Kiiffner, C., & Elstner, E. F. (1993) · Zeitschrift für Naturforschung C · doi:10.1515/znc-1993-1-211 · Cited by 18
Sydow, K., & Böger, R. H. (2001) · PubMed · doi:10.1007/s003920170206 · Cited by 17
Carrieri, P. B., Indaco, A., Gentile, S., Troisi, E., & Campanella, G. (1990) · Current Therapeutic Research · Cited by 10
Cited by
HLH‐2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis
Henter, J., Horne, A., Aricó, M., Egeler, R. M., Filipovich, A. H., Imashuku, S., Ladisch, S., McClain, K., Webb, D., Winiarski, J., et al. (2007) · Pediatric Blood & Cancer · doi:10.1002/pbc.21039 · Cited by 5,386
Treatment of Early Childhood Medulloblastoma by Postoperative Chemotherapy Alone
Rutkowski, S., Bode, U., Deinlein, F., Ottensmeier, H., Warmuth-Metz, M., Soerensen, N., Graf, N., Emser, A., Pietsch, T., Wolff, J. E. A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042176 · Cited by 751
Self-citationKohler, N., Sun, C., Fichtenholtz, A., Gunn, J., Fang, C., & Zhang, M. (2006) · Small · doi:10.1002/smll.200600009 · Cited by 424
Methotrexate-Induced Neurotoxicity and Leukoencephalopathy in Childhood Acute Lymphoblastic Leukemia
Bhojwani, D., Sabin, N. D., Pei, D., Yang, J. J., Khan, R. B., Panetta, J. C., Krull, K. R., Inaba, H., Rubnitz, J. E., Metzger, M. L., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.0808 · Cited by 400
Dextromethorphan: An update on its utility for neurological and neuropsychiatric disorders
Nguyen, L., Thomas, K. L., Lucke-Wold, B. P., Cavendish, J. Z., Crowe, M. S., & Matsumoto, R. R. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.01.016 · Cited by 141
Metadata
- Authors
- Vezmar, S., Becker, A., Bode, U., & Jaehde, U.
- Venue
- Chemotherapy
- Publisher
- S. Karger AG
- Published
- 2003
- Volume
- 49
- Issue
- 1-2
- Pages
- 92-104
- ISSN
- 0009-3157 (ISSN-L)
- 1421-9794
- OpenAlex
- W2019157740
- Cited by
- 267
- References
- 76
- FWCI
- 4.71
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.